201b – Cancer Panel – Lymphoma

*This panel may be listed as 201b – indicating that the Neoplasia Index is modified for specific use in Lymphoma to improve sensitivity and specificity for that application.  All other features remain the same.

Background:

The VDI Cancer Panel (LSA) is for the diagnosis and monitoring of Lymphoma in the sick dog or cat.  Unifying a blood marker of abnormal cell proliferation, Thymidine Kinase Type 1 (TK1) and inflammatory marker CRP or HPT (species dependent) into the Neoplasia Index­, the Cancer Panel is a Rule-in for Lymphoma.   The Cancer Panel (LSA) utilizes a different algorithm to determine the Neoplasia Index for lymphoma-specific cancer diagnosis which improves sensitivity and specificity for this specific application. Additionally, VDI provides context-sensitive results interpretation and clinical review on all Cancer Panels.  Learn More.

Clinical Applications:

1. Suspected Lymphoma
   • Involved lymph nodes
   • ADR (Ain’t Doing Right)
   • Suspicious signs/imaging
2. Confirmed Cancer
   • Monitor Therapy Efficacy
   • Monitor disease progression
   • Determine remission & identify early signs of relapse
   • Identify metastatic disease

Recommendations:

The Cancer Panel (LSA) should be performed prior to administration of steroids, chemo, NSAIDs or other therapy whenever possible.  VDI can interpret results around the presence of therapy, but please be sure to indicate on the Test Requisition Form any medications at the time of draw.

Repeat testing (monitoring) is suggested at varying time windows depending on the patient status, diagnosis, and application.  Contact VDI for consultation on any case to determine the best repeat test window.